<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005260</url>
  </required_header>
  <id_info>
    <org_study_id>21-000908</org_study_id>
    <nct_id>NCT05005260</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine Single-Injection Interscalene Block vs. Continuous Interscalene Block for Primary Total Shoulder Arthroplasty</brief_title>
  <official_title>Prospective, Randomized Clinical Trial Comparing Analgesic Efficacy of Liposomal Bupivacaine Single-Injection Interscalene Blockade to Continuous Interscalene Blockade for Patients Undergoing Primary Total Shoulder Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess analgesia efficacy between liposomal bupivacaine single injection&#xD;
      interscalene blockade vs. continuous interscalene nerve block for patients undergoing primary&#xD;
      total shoulder arthroplasty.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Unblinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain intensity scores</measure>
    <time_frame>Post-Operative Day 1</time_frame>
    <description>Self-reported pain intensity scores measure using pain scores of 0 (no pain) to 10 (worst pain imaginable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>Post-Operative Day 1</time_frame>
    <description>Reported in mg oral morphine equivalents (OME)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of recovery score (QoR)</measure>
    <time_frame>up to post-operative day 7</time_frame>
    <description>15 item short form patient survey using a scoring system evaluating 5 dimensions of health: psychological support, comfort, emotions, physical independence, and pain. The 11-point numerical rating scale leads to a minimum score of 0 (very poor recovery) and a maximum score of 150 (excellent recovery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall benefit of analgesic score (OBAS)</measure>
    <time_frame>up to post-operative day 7</time_frame>
    <description>Patient survey assessing patient experience with postoperative pain regimen. 7 question scoring system entails a combination of pain intensity, adverse opioid events, and patient satisfaction. The total OBAS score is calculated via 'sum items Q1 through Q6 and add [4 - score from Q7].' This score consists of a 29-point scale ranging from 0 (best) to 28 (worst); therefore, lower OBAS scores indicate more analgesic benefit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Brachial Plexus Block</condition>
  <arm_group>
    <arm_group_label>liposomal bupivacaine single-shot interscalene blockade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive a preoperative single-injection interscalene nerve block with long-acting numbing medicine, liposomal bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>continuous interscalene nerve blockade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive a preoperative interscalene nerve block with a continuous catheter device which provides local anesthetic, bupivacaine, for up to 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl</intervention_name>
    <description>Subjects randomized to the continuous interscalene nerve block group will receive a loading dose of 15-20 mL bupivacaine HCl 0.5% followed by a continuous catheter infusion of bupivacaine 0.2% at 8 mL per hour for 72 hours.</description>
    <arm_group_label>continuous interscalene nerve blockade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine + Bupivacaine Hcl 0.5% Inj</intervention_name>
    <description>Subjects will receive a one-time interscalene nerve block injection of 5 mL of bupivacaine 0.5% (25 mg) admixed with 10 mL of liposomal bupivacaine (133 mg).</description>
    <arm_group_label>liposomal bupivacaine single-shot interscalene blockade</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Adult patients with an American Society of Anesthesiologists (ASA) physiological&#xD;
             status I-III&#xD;
&#xD;
          -  Patients presenting for unilateral primary total shoulder arthroplasty (includes&#xD;
             anatomic and reverse total shoulder arthroplasty).&#xD;
&#xD;
          -  Patients 18 years of age and older&#xD;
&#xD;
          -  Able to provide informed consent for him or herself&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Chronic pain syndromes&#xD;
&#xD;
          -  Chronic opioid use (&gt;1 month) with OME &gt;5 mg/day OR acute opioid use (&lt; 1 month) with&#xD;
             OME &gt; 30 mg/day.&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 45 kg/m2&#xD;
&#xD;
          -  Severe drug allergy* to medications used in this study, including non-steroidal&#xD;
             anti-inflammatory drugs (i.e. celecoxib) and local anesthetics. *defined as an immune&#xD;
             reaction resulting in shortness of breath, hives, anaphylaxis, wheezing, and fever&#xD;
&#xD;
          -  Personal or family history of malignant hyperthermia.&#xD;
&#xD;
          -  Major systemic medical problems such as:&#xD;
&#xD;
               -  Pre-existing severe renal disorder defined as glomerular filtration rate (GFR)&#xD;
                  &lt;50 units/m2 (if labs are available), currently on dialysis, or highly suspected&#xD;
                  based on history.&#xD;
&#xD;
               -  Severe hepatic disorder defined as current or past diagnosis of acute/subacute&#xD;
                  necrosis of liver, acute hepatic failure, chronic liver disease, cirrhosis&#xD;
                  (primary biliary cirrhosis), chronic hepatitis/toxic hepatitis, liver abscess,&#xD;
                  hepatic coma, hepatorenal syndrome, other disorders of liver&#xD;
&#xD;
               -  Pre-existing medical history of moderate to severe pulmonary disease requiring&#xD;
                  medical therapy (obstructive and/or restrictive), use of home oxygen,&#xD;
                  preoperative baseline oxygen saturation &lt; 93% on room air.&#xD;
&#xD;
               -  History of contralateral hemidiaphragm dysfunction (e.g., paralysis) or phrenic&#xD;
                  nerve injury.&#xD;
&#xD;
          -  Contraindication to a regional anesthesia technique (e.g., preexisting neuropathy+ in&#xD;
             the operative extremity, coagulopathy, sepsis, infection at site of injection,&#xD;
             uncooperative, and refusal).&#xD;
&#xD;
             o + pre-existing neuropathy includes sensory and/or motor deficits due to nerve insult&#xD;
             of surgical extremity, radicular symptoms of surgical extremity, history of unresolved&#xD;
             brachial plexus injury/brachial plexopathy, and tumors of the brachial plexus.&#xD;
             Patients with nerve compression distal to site of surgery, such as history of carpal&#xD;
             tunnel syndrome or cubital tunnel syndrome, are NOT considered contraindications to&#xD;
             regional anesthesia.&#xD;
&#xD;
          -  Known to be currently pregnant or actively breastfeeding++&#xD;
&#xD;
             o ++ All surgical patients are currently screened using a standardized Pregnancy&#xD;
             Assessment tool (http://mayoweb.mayo.edu/sp-forms/mc8800-mc8899/mc8801-161.pdf)&#xD;
&#xD;
          -  Impaired cognition (e.g. Alzheimer's disease, moderate to severe dementia,&#xD;
             encephalopathy)&#xD;
&#xD;
          -  Non-English speaking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason K Panchamia, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ronda Esper</last_name>
    <phone>(507) 293-9553</phone>
    <email>Esper.Ronda@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason K Panchamia, DO</last_name>
      <phone>507-284-9698</phone>
      <email>panchamia.jason@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 8, 2021</study_first_submitted>
  <study_first_submitted_qc>August 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Jason K. Panchamia, D.O.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Interscalene nerve block</keyword>
  <keyword>total shoulder arthroplasty</keyword>
  <keyword>pain management</keyword>
  <keyword>OBAS</keyword>
  <keyword>QoR-15</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

